494 related articles for article (PubMed ID: 8710369)
1. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
2. Functional domains of the t(8;21) fusion protein, AML-1/ETO.
Lenny N; Meyers S; Hiebert SW
Oncogene; 1995 Nov; 11(9):1761-9. PubMed ID: 7478604
[TBL] [Abstract][Full Text] [Related]
3. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
4. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
5. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
Erickson PF; Robinson M; Owens G; Drabkin HA
Cancer Res; 1994 Apr; 54(7):1782-6. PubMed ID: 8137293
[TBL] [Abstract][Full Text] [Related]
6. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
[TBL] [Abstract][Full Text] [Related]
7. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.
Shurtleff SA; Buijs A; Behm FG; Rubnitz JE; Raimondi SC; Hancock ML; Chan GC; Pui CH; Grosveld G; Downing JR
Leukemia; 1995 Dec; 9(12):1985-9. PubMed ID: 8609706
[TBL] [Abstract][Full Text] [Related]
8. Analysis of TEL proteins in human leukemias.
Poirel H; Lacronique V; Mauchauffé M; Le Coniat M; Raffoux E; Daniel MT; Erickson P; Drabkin H; MacLeod RA; Drexler HG; Ghysdael J; Berger R; Bernard OA
Oncogene; 1998 Jun; 16(22):2895-903. PubMed ID: 9671410
[TBL] [Abstract][Full Text] [Related]
9. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract][Full Text] [Related]
10. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Licht JD
Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
[No Abstract] [Full Text] [Related]
11. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
12. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
13. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
[TBL] [Abstract][Full Text] [Related]
14. Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21).
Matsushita H; Kobayashi H; Mori S; Kizaki M; Ikeda Y
Biochem Biophys Res Commun; 1995 Oct; 215(2):431-7. PubMed ID: 7487974
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
16. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
17. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
18. Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia.
Sacchi N; Schiaffonati L; Magnani I; Pappalardo C; Hughes AJ; Darfler M; Hoogeveen AT
Oncogene; 1996 Jan; 12(2):437-44. PubMed ID: 8570222
[TBL] [Abstract][Full Text] [Related]
19. AML1 and Pebp2: the gene for a transcription factor is involved in recurring translocations in human acute myeloid leukemia.
Rowley JD
Jpn J Cancer Res; 1994 Dec; 85(12):inside front cover. PubMed ID: 7852178
[No Abstract] [Full Text] [Related]
20. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.
Kitabayashi I; Yokoyama A; Shimizu K; Ohki M
EMBO J; 1998 Jun; 17(11):2994-3004. PubMed ID: 9606182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]